Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Enters Pivotal Phase II Trial
Published Time:
2023-11-10 17:46
Source:
Recently, the initiation of the pivotal Phase II trial for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 project was announced at its first center, the Cancer Hospital Chinese Academy of Medical Sciences. Subsequent recruitment will take place across nearly 30 clinical centers nationwide. This pivotal single-arm Phase II trial, based on positive results from the previous Ib phase and a design agreed upon with the NMPA, will continue enrolling the target patient population at the RP2D level to collect safety and efficacy data for VC004.
About VC004
VC004 is a Class I targeted anti-tumor innovative drug independently developed by Jiangsu Vcare. As a next-generation TRK inhibitor, it is expected to provide a treatment option for patients with NTRK fusion mutations while addressing the unmet clinical need for overcoming resistance to first-generation inhibitors. As a next-generation therapeutic, VC004 demonstrates excellent clinical efficacy and safety. Currently, no next-generation resistance-overcoming drugs are marketed globally. VC004 has the potential to become a leading next-generation TRK inhibitor worldwide.
About NTRK Fusion-Positive Solid Tumors
NTRK gene fusions have been identified as oncogenic drivers in both adult and pediatric patients with a wide range of solid tumors. The NTRK genes (NTRK1, NTRK2, and NTRK3) encode the TRKA, TRKB, and TRKC receptors of the TRK family. These fusions act as drivers in multiple cancers and are found across numerous solid tumor types. Currently, NTRK fusion inhibitors show remarkable efficacy in the clinical practice, holding immense potential in the field of oncology. In China, NTRK gene fusion mutations are found in prevalent cancer types such as lung cancer, colorectal cancer, breast cancer, and thyroid cancer, especially high prevalence in certain rare cancers, including secretory breast carcinoma and salivary gland secretory carcinoma.
Related News
28
2025
/
11
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced that the Phase II clinical study of VC005 topical gel, a self-developed second-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD) in adults in China has successfully completed unblinding and preliminary analysis, yielding positive results.
View Details
11
2025
/
11
Recently, Eratrectinib (VC004), a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), was included in the " Support Anti-tumor drugR&D for Kids (SPARK Plan)" launched by the CDE of the NMPA, become the 5th innovative drug variety in the country to be included in this program. This important progress will accelerate the R&D process of the domestic new anticancer drug Eratrectinib in the field of pediatric oncology, bringing new hope to pediatric oncology patients in China.
View Details
31
2025
/
10
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.
View Details
29
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.
View Details
15
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.
View Details
12
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn